At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk ...

Background: Empirical evidence regarding the relationship between social determinants of health (SDH) and renal outcomes remains limited. Consequently, the objective of this study was to investigate ...

Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

March is National Kidney Month, a time to raise awareness about the importance of kidney health and the need for comprehensive screening to close gaps in care, especially for those living with ...

Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and ...

These symptoms might not always mean kidney disease, but they shouldn’t be ignored. If you experience one or more of these warning signs, it’s best to consult a doctor for proper diagnosis.

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

Cystatin C is emphasized as a preferred biomarker for accurate GFR measurement in CKD assessment. SGLT2i are recommended for CKD patients, regardless of diabetes status, for kidney and ...